Prior therapy with anti-CD20 chimeric antibody (Rituximab) may decrease the risk of acute graft-versus-host disease (GVHD) in patients with non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.

被引：0
|
作者：
Ratanatharathorn, V
Bociek, RG
Pavletic, SZ
Lynch, JC
Ferrara, JLM
Uberti, JP
机构：
[1] Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA
[2] Univ Nebraska, Omaha, NE USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1688
引用
收藏
页码：391A / 391A
页数：1
相关论文
共 50 条
  • [1] Rituximab lymphoma transplant antibody therapy for non-Hodgkin's lymphoma following allogeneic stem cell transplantation.
    Seropian, S
    McGuirk, JP
    Cooper, DL
    BLOOD, 1999, 94 (10) : 387B - 387B
  • [2] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
    Neumann, F
    Martin, S
    Kronenwett, R
    Fischer, C
    Kondakci, M
    Kobbe, G
    Gattermann, N
    Haas, R
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [3] Targeted anti-cancer therapy using a chimeric anti-CD20 antibody in the treatment of non-Hodgkin's B cell lymphoma
    Anderson, DR
    Varns, C
    IMMUNOLOGY, 1996, 89 : SI112 - SI112
  • [4] Bortezomib, rituximab, and risk of graft-versus-host disease (GVHD) after BEAM conditioning for allogeneic stem cell transplantation (alloSCT).
    Chamoun, Kamal
    Gulbis, Alison M.
    Milton, Denai
    Jabbour, Elias
    Turturro, Francesco
    Khouri, Issa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Tobinai, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S85 - S90
  • [6] Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan
    Kensei Tobinai
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S85 - S90
  • [7] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment
    Davis, TA
    Grillo-López, AJ
    White, CA
    McLaughlin, P
    Czuczman, MS
    Link, BK
    Maloney, DG
    Weaver, RL
    Rosenberg, J
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3135 - 3143
  • [8] Treatment of B cell low grade non-Hodgkin's lymphoma (NHL) with anti-CD20 monoclonal antibody Rituximab®
    Federico, M
    Clo, V
    Vinci, G
    Sacchi, S
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
  • [9] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [10] Rituximab (anti-CD20 monoclonal antibody) immunotherapy in patients with B-cell non-Hodgkin's lymphoma:: highly effective treatment of residual disease
    Papajík, T
    Szotkowski, T
    Raida, L
    Hubáek, J
    Faber, E
    Hlusí, A
    Vondráková, J
    Pikalová, Z
    Jedliková, K
    Jarosová, M
    Indrák, K
    LEUKEMIA, 2001, 15 (03) : 510 - 510
12345